Fig. 1From: Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumabMIDAS headache days* across 2 years: A mean headache days ± standard error, and B mean change ± standard error in headache days. MIDAS, Migraine Disability Assessment. *Number of headache days occurring over 3-month (12-week) periods over the course of the trialBack to article page